1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation

US Proposed ACNU Rule Rings Bell About Rx Drugs Marketed After NDAs Eliminated With OTC Switches

 
• By Malcolm Spicer

Proposal for simultaneous Rx and OTC sales of same drug at same dose and indication has CHPA hoping FDA acknowledges Pataday and Voltaren Arthritis Relief are competing with Rx equivalents even though elimination of prescription NDAs was part of approvals for the two switches.

• Source: Shutterstock

The “additional conditions for nonprescription use” proposed rule on facilitating OTC switches in the US reminds the Consumer Healthcare Products Association of marketplace problems for two of the most recent drugs made available nonprescription.

The

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation